Skip to main content

ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

Terminated · NCT06026332

Conditions: Bladder Cancer

At a glance

Research payments reported, 2025
$765,801
U.S. investigators named
32
Sites paid
29
Planned or actual enrollment
202

About the trial

Sponsor
Ferring Pharmaceuticals
Tested
ADSTILADRIN (drug)
Dates
Started 2023-09-15; completion 2026-01-15
Results posted
Not yet

Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting

From ClinicalTrials.gov, last updated 2026-02-17. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Ferring Pharmaceuticals As reported $765,801 in research payments for this study in 2025 (146 payments).

Products named: Adstiladrin

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.